C045P: Efalizumab Biosimilar, Anti-human CD11a Monoclonal Antibody

Catalog No.: C045P | **Product Name:** Efalizumab Biosimilar, CD11a Monoclonal Antibody

Efalizumab Biosimilar, CD11a Monoclonal Antibody. The research grade Efalizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

PRODUCT SPECIFICATIONS

Catalog No.	C045P
Product Name	Efalizumab Biosimilar, CD11a Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Integrin, alpha L, antigen CD11A, p180, lymphocyte function-associated antigen 1, alpha polypeptide, ITGAL, LFA-1, LFA1A, integrin subunit alpha L
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype	Humanized IgG1.
Source/Host	The anti-human CD11a monoclonal antibody efalizumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The research grade efalizumab biosimilar specifically binds to the human CD11a.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by efalizumab.
Form Of Antibody	0.2 μM filtered solution, pH 6.0, no stabilizers or preservatives.
Endotoxin	<1 EU/mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade efalizumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Efalizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

REFERENCES & BACKGROUND

What is Efalizumab biosimilar research grade? Efalizumab Biosimilar uses the same protein sequences as the therapeutic antibody efalizumab. Efalizumab is a monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis. Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. Efalizumab binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. As a result efalizumab decreases cell surface expression of CD11a.